Genknowme

May 9, 2023

Success 09.05.2023 For the third consecutive and final year, Genknowme has won the support of the Biôpole Start-up Fund. Since 2021, the Swiss startup co-founded by Semira and Sébastien Nusslé has been gaining market traction and attracting prestigious clients such as La Prairie Clinique in Clarens. Committed to sustain constant innovation, the startup is expanding in the Swiss German part of Switzerland, and internationally, in Spain and the UK. Three years ago, Genknowme started collaborating with La Prairie Clinique. A partnership of key importance for the Swiss Epigenetic startup as La Prairie Clinique is a leading innovator in the realm of longevity. Speaking of the collaboration, Co-Founder and Chief Medical Officer Semira Gonseth Nusslé tells Startupticker.ch: “Working closely with them has allowed us to refine and enhance its products based on their valuable feedback. Our mutual objectives and principles align seamlessly, driving us to continuously seek advancements and broaden our range of services.” Today Genknowme performs all the epigenetic testing for Clinique La Prairie’s clients. To date, Genknowme has conducted tests on over 500 patients across various clinics. The responses from both medical professionals and patients have been globally highly positive. Its assessments allow to validate the efforts of health-conscious individuals while occasionally uncovering surprising results that prompt necessary adjustments. For those with suboptimal lifestyles, the outcomes provide motivation to adopt healthier habits. The startup continually draws upon these insights and experiences to refine and improve its services and offerings. Biopôle Fund's support has been instrumental in Geknowme’s growth. Semira Gonseth Nusslé explains how the fund has helped her company: ‘Over the past two years, the Biopôle Start-up Fund has been a valuable partner for our company. With its support, we’ve expanded our presence in both the Swiss and European markets. Additionally, we made significant progress in our R&D efforts, resulting in the development of several new products that will soon be available to our customers. The fund’s financial backing also allowed us to equip our laboratory to be fully self-sufficient. Overall, our partnership with the Biopôle Start-up Fund has solidified our position in the market and positioned us for future investment opportunities.’ Despite the COVID period being a difficult time to launch such a service, Genknowme has been growing steadily. Currently, the company has about 15 B2B clients, including the High Care Center from Hospital La Tour in Geneva and the Clinique Suisse in Montreux. The startup also started to expand in the Swiss German part of Switzerland (Sweet Skin in Baar), and internationally, in Spain (RoseBar in the Six Senses spa in Ibiza) and in the UK (Wellgevity). In the coming year, Genknowme is dedicated to a roadmap that emphasizes laboratory automation, custom report generation, and expanding its offerings in areas like nutrition, physical activity, chronic inflammation, and environmental factors. Co-founder Semira Gonseth Nusslé adds: “We will continue our expansion on the European market. There is a significant program of R&D in collaboration with an academic institution that will help us to sustain constant innovation.” Applications open for Biopôle Startup Fund Together with Epalinges based Testmate Health and Alithea Genomics, Genknowme is one of the start-ups that will be supported again this year by the Biopôle Start-up Fund. The program offers up to CHF 90,000 per year for three consecutive years to promising companies in the life sciences. Companies interested in the Biopôle Start-up Fund can find all necessary information here . The next deadline for applications is June 2, 2023. (ES)